NKGNW
Income statement / Annual
Last year (2023), NKGen Biotech, Inc. Warrants's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, NKGen Biotech, Inc. Warrants's net income was -$82.95 M.
See NKGen Biotech, Inc. Warrants’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00
|
$77,000.00
|
$426,000.00
|
| Cost of Revenue |
$1.20 M |
$18,000.00 |
$30,000.00 |
| Gross Profit |
-$1.20 M |
$59,000.00 |
$396,000.00 |
| Gross Profit Ratio |
0 |
0.77 |
0.93 |
| Research and Development
Expenses |
$14.47 M
|
$16.75 M
|
$14.67 M
|
| General & Administrative
Expenses |
$0.00
|
$7.66 M
|
$7.59 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$14.08 M
|
$7.66 M
|
$7.59 M
|
| Other Expenses |
$0.00 |
-$95,000.00 |
-$84,000.00 |
| Operating Expenses |
$28.54 M |
$24.41 M |
$22.26 M |
| Cost And Expenses |
$29.75 M |
$24.42 M |
$22.29 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$745,000.00 |
$2.31 M |
$1.32 M |
| Depreciation &
Amortization |
$1.20 M
|
$1.21 M
|
$1.24 M
|
| EBITDA |
-$28.54 M
|
-$23.23 M
|
-$20.70 M
|
| EBITDA Ratio |
0 |
-295.99 |
-48.59 |
| Operating Income Ratio
|
0
|
-316.18
|
-51.32
|
| Total Other
Income/Expenses Net |
-$53.20 M
|
-$2.40 M
|
-$1.40 M
|
| Income Before Tax |
-$82.95 M |
-$26.75 M |
-$23.26 M |
| Income Before Tax Ratio
|
0
|
-347.36
|
-54.6
|
| Income Tax Expense |
$7,000.00 |
$7,000.00 |
$5,000.00 |
| Net Income |
-$82.95 M |
-$26.75 M |
-$23.27 M |
| Net Income Ratio |
0 |
-347.45 |
-54.61 |
| EPS |
-5.38 |
-4.21 |
-1.08 |
| EPS Diluted |
-5.38 |
-4.21 |
-1.08 |
| Weighted Average Shares
Out |
$15.43 M
|
$6.36 M
|
$21.45 M
|
| Weighted Average Shares
Out Diluted |
$15.43 M
|
$6.36 M
|
$21.45 M
|
| Link |
|
|
|
